EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study

Lourdes García-Carnero, Gabriela Abelenda-Alonso iD, Marc Santos-Puig, Ariadna Padullés, Clara Ribera iD, Alberto Lamiel, Rosa Costa-Primo, Manuel González de Aledo, Rosa Granada, Víctor Daniel Gumucio iD, Eva Santafosta, Marc Gilabert und 5 weitere

Antibiotics · 20.04.2026 · 15 (4) · 416

DOI: 10.3390/antibiotics15040416 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Antibiotics, online erschienen am 20.04.2026. Verfasst von Lourdes García-Carnero und 16 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) represent a major therapeutic challenge, particularly in hospitalized and critically ill patients with limited treatment options. Cefiderocol, a novel siderophore cephalosporin, has demonstrated activity against a broad range of resistant Gram-negative pathogens. We aimed to evaluate the effectiveness and safety of cefiderocol for the treatment of MDR-GNB infection.

Methods

We conducted a retrospective observational study including all adult patients who received ≥72 h of cefiderocol between November 2020 and October 2024 at a Spanish tertiary-care hospital. The primary outcome was clinical success, defined as survival and absence of clinical recurrence 30 days after cefiderocol initiation. Secondary outcomes included 30- and 90-day mortality, clinical and microbiological recurrence, emergence of resistance, and adverse events.

Results

Eighty patients were included (median age 64 years [IQR 56–72]; 81.3% male). Respiratory (26.2%) and abdominal (22.5%) infections were the most common, and 20% presented with bacteremia. At infection onset, 26.2% had septic shock and 45% required intensive care unit admission. The three most frequently isolated pathogen was Pseudomonas aeruginosa (33.9%), followed by Enterobacterales (33%) and Stenotrophomonas maltophilia (30.1%). Clinical success was achieved in 67.5% of patients. Thirty and 90-day mortality rates were 27.5% and 36.5%, respectively. Recurrence within 90 days occurred in 5% of cases. Emergence of resistance was detected in one Klebsiella pneumoniae ST147 isolate, and serious adverse events occurred in 5% of patients.

Conclusions

In a cohort including a substantial proportion of critically ill patients, cefiderocol was associated with favorable clinical outcomes and an acceptable safety profile. These findings suggest that cefiderocol may represent a useful therapeutic option for severe MDR-GNB infections in patients with limited treatment alternatives.

Schlagwörter

Stichwörter der Autor:innen

Pseudomonas aeruginosaStenotrophomonas maltophiliacarbapenem-resistant Enterobacteralescefiderocolmultidrug-resistant Gram-negative bacteria

Autor:innen und Institutionen

  • Infectious Diseases Department, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Spain.
  • Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Spain.
  • Research Network for Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Pharmacy Department, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Spain.
  • Microbiology Department, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Spain.
  • Department of Intensive Care, Bellvitge University Hospital, 08907 L'Hospitalet de Llobregat, Spain.

ORCID-Profile: Gabriela Abelenda-Alonso, Clara Ribera, Víctor Daniel Gumucio, Mireia Puig-Asensio, Evelyn Shaw, Jordi Carratalà, Carlota Gudiol

Zitieren

APA

García-Carnero, L., Abelenda-Alonso, G., Santos-Puig, M., Padullés, A., Ribera, C., Lamiel, A., Costa-Primo, R., Aledo, M. G., Granada, R., Gumucio, V. D., Santafosta, E., Gilabert, M., Blanco-Arévalo, A., Puig-Asensio, M., Shaw, E., Carratalà, J., & Gudiol, C. (2026). Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study. Antibiotics, 15(4), 416. https://doi.org/10.3390/antibiotics15040416

Vancouver

García-Carnero L, Abelenda-Alonso G, Santos-Puig M, Padullés A, Ribera C, Lamiel A, et al. Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study. Antibiotics. 2026;15(4):416. doi:10.3390/antibiotics15040416

BibTeX
@article{GarcaCarnero2026,
  author = {García-Carnero, Lourdes and Abelenda-Alonso, Gabriela and Santos-Puig, Marc and Padullés, Ariadna and Ribera, Clara and Lamiel, Alberto and Costa-Primo, Rosa and Aledo, Manuel González de and Granada, Rosa and Gumucio, Víctor Daniel and Santafosta, Eva and Gilabert, Marc and Blanco-Arévalo, Alejandro and Puig-Asensio, Mireia and Shaw, Evelyn and Carratalà, Jordi and Gudiol, Carlota},
  title = {Cefiderocol Targeted Treatment for Multidrug-Resistant Gram-Negative Infections: An Observational Cohort Study},
  journal = {Antibiotics},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {416},
  doi = {10.3390/antibiotics15040416}
}
Kostenlos starten →